xigduo
Botanicalexperimental
Dapagliflozin/metformin, sold under the brand name Xigduo Xr among others, is a fixed-dose combination anti-diabetic medication used as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes. It is a combination of dapagliflozin and metformin and is taken by mouth. Dapagliflozin/metformin was approved for use in the European Union in January 2014, in the United States in February 2014, and in Australia in July 2014. — Wikipedia
Clinical trial activity
2 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
1
Earliest trial started Mar 1, 2016 (NCT02722239)
Timeline
2010s
- Jan 1, 2016
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Unspecified targetUnclear
Unclear
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaDapagliflozin/metformin ↗
Also known as
- xigduo
- xigduo
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06327815 | Phase 4 | Mar 15, 2024 | AstraZeneca, Capital Medical University |
| NCT02722239 | Phase 1 | Mar 1, 2016 | AstraZeneca, Biocard |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| AstraZeneca | For profit | 2 | 2 | 2 | 2016 |
| Biocard | For profit | 1 | 0 | 1 | 2016 |
| Capital Medical University | Academic/Hospital | 1 | 0 | 1 | 2024 |
3 organizations
Page 1 / 1